While most stocks currently receiving new Buy or Outperform analyst ratings have upside potential of 8% to 10%, the author of today’s article reminds the reader that “There is another type of Buy rating that is far more speculative, one in which the projected upside can be 50%, 100% or exponentially higher.” He proceeds to highlight five biotech stocks that currently fall into this category – with upside potential ranging from 100% to 400%. For these five biotechs – as well as a couple of runners-up with under-100% (but still high) upside potential – CLICK HERE.